3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Terminated
2
Recruiting
2
Active not recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Thoracic
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Endocrine
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Dermatologic
1
CNS
1
Conditions
Brain Neoplasms
101
Glioblastoma
85
Glioma
58
Central Nervous System Neoplasms
34
Astrocytoma
27
Neuroblastoma
26
Gliosarcoma
19
Breast Neoplasms
19
Neoplasms
18
Oligodendroglioma
17
Recurrence
14
Neoplasm Metastasis
13
Medulloblastoma
12
Ependymoma
11
Carcinoma, Non-Small-Cell Lung
11
Lymphoma
9
Sarcoma
8
Osteosarcoma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neuroma, Acoustic
7
Meningioma
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Follicular
7
Lung Neoplasms
7
Hodgkin Disease
7
Burkitt Lymphoma
7
Wilms Tumor
6
Sezary Syndrome
6
Neuroectodermal Tumors, Primitive
6
Mycosis Fungoides
6
Interventions
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms, Unknown Primary
×
CNS
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn